Philipp Spycher | Chief Executive Officer
Araris Biotech AG

Philipp Spycher, Chief Executive Officer, Araris Biotech AG

Philipp Spycher is the co-founder and CEO of Araris Biotech AG. Philipp incorporated Araris after winning the PSI Founder Fellowship as well as several other prices and grants to commercialize the Araris Linker Technology. During his post-doctoral work at the Paul Scherrer Institute (PSI, Switzerland), he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris Linker Technology. He obtained his Master’s Degree and Ph.D. from ETH Zurich (Switzerland) at the interface of Material Science and Protein Engineering.

Appearances:



Festival of Biologics Day 1 @ 17:30

A CD79b targeting ADC with superior anti-tumor activity and therapeutic index using a novel peptide linker technology

  • Introduction of a novel peptide linker technology enabling ADCs to be generated from native antibodies ‘off-the-shelf’ in one step without any engineering step
  • Resulting anti-CD79b ADC is very well defined and shows favorable biophysical properties
  • The anti-CD79b ADC uses a non-cleavable linker resulting in significantly reduced neurotoxic and neutropenic effects in ex-vivo studies
  • Data indicate an improved therapeutic index by a factor of 6 compared to FDA-approved ADC 
Philipp Spycher, Chief Executive Officer, Araris Biotech AG
last published: 01/Jul/22 16:05 GMT

back to speakers